Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3912

Sort by

Sort Order Select

Journal Articles

Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism

Bethany Verkamp, Sonata Jodele, Anthony Sabulski, Rebecca Marsh, Pearce Kieser, Michael B. Jordan

Blood (2024) 144 (25): 2625–2636.

https://doi.org/10.1182/blood.2024025977

Published: 2024

Includes: Supplemental data

Journal Articles

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

Austin G Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-ichi Nishimura, Christopher J Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jens Peter Panse, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre de Fontbrune, Antonio Maria Risitano, Jong Wook Lee

Blood blood.2024026299.

https://doi.org/10.1182/blood.2024026299

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood (2024) 144 (25): 2678–2681.

https://doi.org/10.1182/blood.2024025683

Published: 2024

Includes: Supplemental data

Journal Articles

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Blood (2024) 144 (24): 2490–2502.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance

Camille Laurent, Preeti Trisal, Bruno Tesson, Sahil Seth, Alicia Beyou, Sandrine Roulland, Bastien Lesne, Nathalie Van Acker, Juan-Pablo Cerapio, Loïc Chartier, Arnaud Guille, Matthew E. Stokes, C. Chris Huang, Sarah Huet, Anita K. Gandhi, Franck Morschhauser, Luc Xerri

Blood (2024) 144 (24): 2503–2516.

https://doi.org/10.1182/blood.2024024496

Published: 2024

Includes: Supplemental data

Journal Articles

Rates of strokes in Californians with sickle cell disease in the post-STOP era

Olubusola Oluwole, Ann M. Brunson, Oyebimpe O. Adesina, Shaina M. Willen, Theresa H. M. Keegan, Kleber Yotsumoto Fertrin, Ted Wun

Blood (2024) 144 (24): 2517–2527.

https://doi.org/10.1182/blood.2023023031

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun A Fleming, Chun Yew Fong, Uma Borate, Meagan A Jacoby, Daniel Nowak, Maria R Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood blood.2024025464.

https://doi.org/10.1182/blood.2024025464

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Recurrent CLTC :: SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue

Blood (2024) 144 (23): 2439–2455.

https://doi.org/10.1182/blood.2024025127

Published: 2024

Includes: Supplemental data

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don M Benson, Jr, Maria Chaudhry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Christine Collins, Xavier Parot, Jonathan L Kaufman

Blood blood.2024026124.

https://doi.org/10.1182/blood.2024026124

Published: 2024

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Blood blood.2024024681.

https://doi.org/10.1182/blood.2024024681

Published: 2024

Includes: Supplemental data

Journal Articles

Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study

Cornelia Englisch, Florian Moik, Daniel Steiner, Angelika M. Starzer, Anna S. Berghoff, Matthias Preusser, Ingrid Pabinger, Cihan Ay

Blood (2024) 144 (22): 2349–2359.

https://doi.org/10.1182/blood.2024025362

Published: 2024

Includes: Supplemental data

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited

Jan-Inge Henter, Elena Sieni, Julia Eriksson, Elisabet Bergsten, Ida Hed Myrberg, Scott W. Canna, Maria Luisa Coniglio, Randy Q. Cron, Kate F. Kernan, Ashish R. Kumar, Kai Lehmberg, Francesca Minoia, Ahmed Naqvi, Angelo Ravelli, Yong-Min Tang, Matteo Bottai, Yenan T. Bryceson, AnnaCarin Horne, Michael B. Jordan

Blood (2024) 144 (22): 2308–2318.

https://doi.org/10.1182/blood.2024025077

Published: 2024

Includes: Supplemental data

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood blood.2024025868.

https://doi.org/10.1182/blood.2024025868

Published: 2024

Includes: Supplemental data

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

NARROW

Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance

Rates of strokes in Californians with sickle cell disease in the post-STOP era

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Recurrent CLTC :: SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only